ACHN - Achillion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6300
+0.0400 (+1.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.5900
Open3.6300
Bid0.0000 x 1000
Ask0.0000 x 2900
Day's Range3.6100 - 3.7350
52 Week Range1.2900 - 5.0300
Volume1,487,079
Avg. Volume1,783,710
Market Cap507.086M
Beta (3Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BLUE BELL, Pa., Sept. 26, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.

  • GlobeNewswire

    Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients with paroxysmal nocturnal hemoglobinuria (PNH) who are sub-optimal responders to  a C5 inhibitor alone.  The FDA’s decision was based on positive safety and efficacy data from the ongoing danicopan Phase 2 PNH combination trial. Interim data was reported at the New Era of Aplastic Anemia and PNH Meeting in May 2019.

  • GlobeNewswire

    Achillion to Present at the Baird 2019 Global Healthcare Conference

    BLUE BELL, Pa., Aug. 29, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.

  • GlobeNewswire

    Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    – Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities.

  • GlobeNewswire

    Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

    The study also included a single dose cohort of 240 mg. The results demonstrated that ACH-5228, when dosed 120 mg BID or higher, achieved near complete and sustained Alternative Pathway (AP) inhibition with a mean value of 95% at steady state concentrations as measured by AP Hemolysis and AP Wieslab assays. With its improved potency and longer durability of effect, we believe that oral ACH-5228 has the potential to be the best-in-class alternative pathway inhibitor. Danicopan, our first-generation alternative pathway inhibitor, validated factor D as a target and we plan to begin a Phase 3 registrational study in early 2020,” said Joe Truitt, Chief Executive Officer of Achillion Pharmaceuticals.

  • GlobeNewswire

    Achillion to Present at the JMP Securities Life Sciences Conference

    BLUE BELL, Pa., June 13, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.

  • GlobeNewswire

    Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH-4471 (newly designated “danicopan”) proof of concept Phase 2 trial in untreated patients with paroxysmal nocturnal hemoglobinuria (PNH) was accepted for oral presentation at the 24th Congress of the European Hematology Association (EHA). The 24th Congress of the EHA is being held in Amsterdam, Netherlands from June 13 – 16, 2019.

  • GlobeNewswire

    Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

    - ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019.

  • GlobeNewswire

    Achillion Granted Twentieth Patent for Factor D Portfolio

    BLUE BELL, Pa., May 14, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.

  • GlobeNewswire

    Achillion Reports First Quarter 2019 Financial Results

    - PNH combo Phase 2 trial interim data to be presented May 17, 2019 -- C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND.

  • GlobeNewswire

    Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy (C3G), a devastating disease affecting the kidney for which there is no approved therapy. ACH-4471 will be evaluated in the six-month blinded, placebo-controlled trial (11 patients) and the 12-month open-label trial (12 patients). “Enrolling our ACH-4471 Phase 2 trials is an important milestone for Achillion, and we would like to thank all of the patients, families, investigators and participating clinical trial sites for their outstanding contributions,” said Joe Truitt, President and Chief Executive Officer at Achillion.

  • GlobeNewswire

    Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial

    In the Phase 2 trial, patients with an inadequate response to eculizumab as monotherapy are being evaluated for increases in hemoglobin and reduced transfusions over 24-weeks. Early data released in December 2018 provided evidence that ACH-4471 in combination with eculizumab had a positive impact on patient hemoglobin and FACIT-fatigue scores while reducing transfusions, reticulocyte counts and LDH levels.

  • GlobeNewswire

    Achillion to Present at the Barclays Global Healthcare Conference

    BLUE BELL, Pa., March 08, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.

  • GlobeNewswire

    Achillion Reports Fourth Quarter and Full Year 2018 Financial Results

    - Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 -- Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting -- Next-generation.

  • GlobeNewswire

    Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market

    NEW HAVEN, Conn., Feb. 21, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire

    Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference

    NEW HAVEN, Conn., Feb. 19, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire

    Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Achillion Appoints Brian Di Donato as Chief Financial Officer

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately. Mr. Di Donato has over 20 years of financial and leadership experience and will assume responsibility for finance, accounting and treasury as well as continue to lead investor relations. “Brian joined the Achillion team in August 2018 and has already made significant contributions alongside the new management team as we accelerate our clinical programs and prepare for registrational trials,” commented Joseph Truitt, President and Chief Executive Officer of Achillion.

  • GlobeNewswire

    Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

    - ACH-5228, with improved potency and half-life, increases alternative pathway inhibition -- Achillion planning Investigational New Drug (IND) submission in fourth quarter of.

  • GlobeNewswire

    Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system, today announced that the Company’s Board of Directors has elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain Associates LLC and has been a member of Achillion's Board of Directors since September 2010.

  • ACCESSWIRE

    4 Healthcare Stocks That Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Shares of Achillion Pharmaceuticals were in the red on Monday as traders waited for interim clinical-trial data from the company. Synergy Pharmaceuticals saw its shares explode on news from Cipher Pharmaceuticals Inc. announcing that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide from Synergy earlier this year.

  • GlobeNewswire

    Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated disorders, today reported interim results for the Company’s Phase 2 trials of its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and potency data for its next-generation factor D inhibitors, ACH-5228 and ACH-5548. “These compelling findings underscore the momentum for Achillion and our factor D portfolio as we advance three oral small molecule compounds through clinical development.

  • GlobeNewswire

    Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced today that the company will host a live webcast and conference call on December 17th at 4:30PM EST. Joseph Truitt, President and Chief Executive Officer and Dr. Stephen Zelenkofske, Executive Vice President and Chief Medical Officer will present Achillion’s 2019 development plans along with interim data for the Company’s Phase 2 clinical trials in PNH and C3G as well as initial Phase 1 data on Achillion’s next generation factor D inhibitors.

  • GlobeNewswire

    Achillion Reports Third Quarter 2018 Financial Results

    - Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy -- Interim data and strategic update planned for December 17, 2018 –- September 30, 2018 cash.